Meihua International Medical Technologies Co Ltd (MHUAF) AI Stock Analysis

• Market Cap: $7.63M
• Dividend Yield: N/A
• Average Volume (3M): 258.45K
• Price to Earnings (P/E): 1.0
• Beta (1Y): 1.13
• Revenue Growth: -4.99%
• EPS Growth: -19.10%
• Country: US
• Employees: 619
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.86
• Shares Outstanding: 857,914
• 10 Day Avg. Volume: 415,554
• 30 Day Avg. Volume: 258,455
• PEG Ratio: -0.05
• Price to Book (P/B): 0.06
• Price to Sales (P/S): 0.10
• P/FCF Ratio: 0.65
• Enterprise Value/Market Cap: 0.27
• Enterprise Value/Revenue: 0.02
• Enterprise Value/Gross Profit: 0.07
• Enterprise Value/Ebitda: 0.16
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 65 Neutral
• Price Target: $12.00 ▲(100.00% Upside)
• Action: Upgraded Date: 01/28/26
• Date: Action: Upgraded 01/28/26

The score is driven primarily by solid financial performance (strong operating margins and low leverage) tempered by inconsistent free cash flow. Technicals detract due to weak longer-term trend signals and negative MACD despite stretched momentum readings, while the very low P/E supports the overall score.

Positive Factors

Strong Operating Margins

Sustained strong EBIT/EBITDA and stable gross margins indicate durable operating efficiency and pricing power in medical devices. This supports reinvestment in R&D and manufacturing, cushions against input cost shocks, and underpins long‑term profitability even with cyclical demand.

Low Leverage / Strong Equity

Low leverage and a solid equity base provide financial flexibility for capital expenditures, R&D, and bidding on government tenders. This reduces refinancing risk, lowers interest burden, and preserves optionality for strategic investments over the next several quarters.

Recent Capital Raises & Investor Lock-up

Material private placements bolstered liquidity for working capital and operations. The 12‑month lock-up signals longer‑term investor commitment and reduces immediate secondary selling, giving management runway to execute strategy and stabilize operations over the medium term.

Negative Factors

Declining Revenue & EPS

Negative topline and EPS trends suggest persistent demand or pricing pressures and weaken internal cash generation prospects. Continued declines can erode scale advantages, constrain R&D and commercial investment, and make margin maintenance harder across coming quarters.

Volatile / Occasionally Negative Free Cash Flow

Unstable free cash flow limits the company’s ability to self‑fund capex, R&D, and working capital, increasing reliance on external financing. Over time this can raise funding costs, slow product development, and heighten execution risk for tenders and strategic initiatives.

Auditor Change May Raise Governance Scrutiny

Replacing the auditor can trigger investor and creditor scrutiny around financial controls and reporting continuity. Even without reported disagreements, such changes may raise perception risks, prompt closer regulatory or partner due diligence, and temporarily complicate access to some counterparties.

Meihua International Medical Technologies Co Ltd Business Overview & Revenue Model

Company Description

Meihua International Medical Technologies Co., Ltd. engages in the research and development, manufacture, and sale of medical devices in the People's Republic of China. The company offers Class I disposable medical devices, including disposable medical X-ray films, medical dry films, dry laser imagers, gauze bandages, examination gloves, pharmaceutical packaging materials and containers, low-density polyethylene bottles for eye drops, and high-density polyethylene bottles for tablets; Class II products, such as disposable full anesthesia kits, medical brush, woman's examination kits, urethral catheterization kits, gynecological examination kits, endotracheal intubation, medical masks, anal bags, and suction connecting tube, etc.; and Class III disposable medical devices, such as disposable infusion pumps, anesthesia puncture kits, electronic pumps, etc. It also offers disposable plastic baby bottles, NB/PSN rubber covers and 8.2mL folded spoons for tools and containers, etc.; Class II 6866 medical polymer materials and products, including transfusion equipment and pipelines, endotracheal intubation for respiratory anesthesia or ventilation; and medical x-ray films and multi-functional self-extracting X-ray film machines. The company serves hospitals, pharmacies, medical institutions, and medical equipment companies. It also exports its products to Europe, North America, South America, Asia, Africa, and Oceania. The company was founded in 1991 and is based in Yangzhou, the People's Republic of China.

How the Company Makes Money

MHUA generates revenue through multiple key streams, primarily from the sale of its medical devices and equipment to hospitals, clinics, and healthcare providers. The company leverages a direct sales model coupled with distribution partnerships to reach a broader market. Additionally, MHUA may engage in research and development collaborations with healthcare institutions and other technology firms, potentially leading to licensing agreements or shared revenue from innovative products. Strategic partnerships with healthcare organizations and participation in government tenders for medical supplies further contribute to its earnings, ensuring a diverse and stable income foundation.

Meihua International Medical Technologies Co Ltd Financial Statement Overview

Summary

Financial statements indicate solid overall health: stable revenue and robust EBIT/EBITDA margins (Income Statement 75) supported by low leverage and a strong equity position (Balance Sheet 70). The main constraint is cash-flow quality, with volatile and sometimes negative free cash flow despite improved operating cash flow (Cash Flow 65).

Income Statement

The company has demonstrated consistent revenue generation with slight fluctuations. Gross profit margins remain stable, indicating efficient production or service delivery. However, net profit margins have declined, suggesting increased costs or lower efficiency in managing expenses. The EBIT and EBITDA margins are robust, reflecting strong operating performance.

Balance Sheet

The balance sheet shows a strong equity position with a favorable debt-to-equity ratio, indicating low leverage and financial stability. The return on equity has been positive, suggesting effective use of shareholder funds. However, the equity ratio has seen minor variations, reflecting changes in asset management.

Cash Flow

The cash flow statement reveals a significant improvement in operating cash flows in recent years, enhancing liquidity. Despite this, free cash flow has been volatile, occasionally negative, indicating challenges in managing capital expenditures and cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	89.55M	96.91M	97.10M	103.35M	104.04M	89.06M
Gross Profit	30.64M	33.30M	33.09M	38.10M	39.81M	37.16M
EBITDA	12.91M	15.70M	15.77M	11.65M	27.03M	24.39M
Net Income	9.27M	10.84M	11.63M	6.24M	20.95M	19.05M
Balance Sheet
Total Assets	190.58M	186.24M	171.92M	163.58M	136.86M	106.05M
Cash, Cash Equivalents and Short-Term Investments	15.55M	15.96M	16.93M	26.74M	8.15M	7.19M
Total Debt	11.45M	7.95M	7.33M	6.81M	5.18M	3.22M
Total Liabilities	25.64M	27.26M	25.08M	24.90M	29.09M	21.31M
Stockholders Equity	164.95M	158.98M	146.33M	138.12M	106.81M	84.74M
Cash Flow
Free Cash Flow	3.59M	14.50M	-2.41M	-11.86M	-904.89K	-10.79M
Operating Cash Flow	3.72M	14.64M	2.28M	-9.16M	-54.66K	5.33M
Investing Cash Flow	-8.91M	-20.42M	-12.46M	-8.62M	-833.82K	-16.09M
Financing Cash Flow	3.39M	6.21M	706.13K	37.25M	1.86M	1.71M

Meihua International Medical Technologies Co Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.00
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MHUAF, the sentiment is Negative. The current price of 6 is below the 20-day moving average (MA) of 9.60, below the 50-day MA of 6.98, and below the 200-day MA of 27.55, indicating a neutral trend. The MACD of 0.15 indicates Positive momentum. The RSI at 48.80 is Neutral, neither overbought nor oversold. The STOCH value of 36.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MHUAF.

Meihua International Medical Technologies Co Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUAF	65 Neutral	$7.63M	1.01	5.90%	―	-4.99%	-19.10%
EKSO	54 Neutral	$35.63M	-1.12	-85.01%	―	-16.59%	43.20%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
WOK	47 Neutral	$1.44M	-2.02	―	―	―	―
LUCY	43 Neutral	$5.89M	-1.28	-74.10%	―	53.22%	72.69%
GCTK	42 Neutral	$1.42M	-0.36	―	―	―	60.83%

Meihua International Medical Technologies Co Ltd Corporate Events

Meihua International Medical Technologies Locks Up Recent Offshore Private Placement Investors for 12 Months

On January 22, 2026, Meihua International Medical Technologies announced that investors in two recent offshore equity financings agreed to a 12‑month lock-up on their holdings, limiting secondary market sales and registrations. The company had raised $15.2 million through an October 8, 2025 private placement of 40 million ordinary shares (equivalent to 400,000 Class A ordinary shares post reverse-split and redesignation), which closed on January 20, 2026, and a further $1.32 million in a December 5, 2025 offering of up to 120,000 Class A ordinary shares that closed on December 15, 2025. Under the new lock-up agreements, all October and December purchasers have committed not to sell, pledge or otherwise dispose of their securities, nor seek registration of those shares, for 12 months following the respective closings without the company’s consent, a move that is expected to support share price stability and signal longer-term commitment from these non-U.S. investors.

The most recent analyst rating on (MHUAF) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Meihua International Medical Technologies Co Ltd stock, see the MHUAF Stock Forecast page.

Meihua International Medical Technologies Replaces Auditor With Li CPA LLC

On December 26, 2025, Meihua International Medical Technologies Co., Ltd., a China-based medical devices and healthcare products supplier, dismissed Kreit & Chiu CPA LLP as its independent registered public accounting firm and appointed Li CPA LLC to audit its financial statements for the year ended December 31, 2025. The company emphasized that Kreit & Chiu’s audit reports for fiscal years 2022 through 2024 contained no adverse opinions or qualifications and that there were no disagreements or reportable events related to accounting practices, disclosures, or audit procedures during that period, suggesting the change reflects a strategic or operational decision rather than a response to audit issues; Kreit & Chiu confirmed its agreement with Meihua’s description of the circumstances in a letter to the U.S. Securities and Exchange Commission on January 7, 2026.

The most recent analyst rating on (MHUAF) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Meihua International Medical Technologies Co Ltd stock, see the MHUAF Stock Forecast page.

Meihua International Medical Technologies Completes December Private Placement

Meihua International Medical Technologies Co., Ltd. recently completed a private placement of 120,000 class A ordinary shares at $11 per share, raising $1.32 million. This follows a previous offering in October 2025, where the company issued 40 million ordinary shares at $0.38 each, generating $15.2 million. The proceeds from the December offering are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and operational capabilities.

The most recent analyst rating on (MHUAF) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Meihua International Medical Technologies Co Ltd stock, see the MHUAF Stock Forecast page.